Exabis Library
Welcome to the e-CCO Library!
P374: Therapeutic drug monitoring can guide the intravenous-to-subcutaneous switch of infliximab and vedolizumab: a pharmacokinetic simulation study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P375 Feasibility of the first paediatric randomised controlled pilot trial of faecal microbiota transplant for ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P375: A simulation study to evaluate the performance of a multiple imputation method to address missing data in an analysis of clinical effectiveness using the ImproveCareNow Registry of pediatric patients with Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P375: Faecal calprotectin variation after induction therapy with infliximab to predict clinical, endoscopic and ultrasonographic remission in Crohn’s disease patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P375: Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multi-centre case series
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P375: Intraoperative endoscopy is safe and helps to determine the resection extent in Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P375: Izencitinib induction treatment in patients with moderately-to-severely-active Crohn's Disease: A phase 2 double-blind, randomized, placebo-controlled study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P375: Long-term outcomes after primary infliximab treatment failure in patients with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P375: Self-management in inflammatory bowel disease: A perspective of patients and caretakers
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P376 Real life health care utilisation in paediatric patients with inflammatory bowel disease in the era of biologics
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P376: Assessment of nutritional status and food related experience of adult inflammatory bowel disease inpatients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P376: Clinical effectiveness of vedolizumab in a tertiary care cohort of IBD patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P376: Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn’s disease: results from the Phase 3b VERSIFY trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P376: Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P376: Improving stress and fatigue in a real-world setting among patients with Inflammatory Bowel Disease through a digital platform
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P376: Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P376: Therapy refractory ulcerative colitis patients may benefit from appendectomy: early result from the PASSION study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P377 Risk factors of rectal amputation for Crohn’s disease with perianal lesion
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P377: Changes over time in the Lémann Index and the Inflammatory Bowel Disease-Disability Index in patients with Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P377: Clinical strategies based on patient-reported outcomes and physicians’ preferences to monitor biological therapy in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM